Glioblastoma is a highly malignant brain tumor for which current therapeutic options provide only a modest improvement in outlook. New treatments of glioblastoma are urgently needed.
Safety results of completed Phase I clinical trials and pre-clinical trials of CX-02 indicated a striking glioblastoma stem cell-killing effect and the ability of CX-02 to reverse temozolomide resistance. Based on the results of these studies, Cantex expects to begin enrolling patients in 2016 into a Phase II clinical human trial of CX-02 in recurrent glioblastoma at major U.S. cancer centers with top-line results from this clinical trial expected in the second half of 2017. CX-02 has been granted Orphan Drug Designation for glioblastoma by the U.S. Food and Drug Administration's Office of Orphan Products Development.